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A Ab bs st tr ra ac ct t    Lichen planus is a mucocutaneous disease of inflammatory nature and 
unknown etiology. It is characterized by a cell-mediated immunological 
response to induced antigenic change in skin and/or mucosa. The possible 
malignant transformation of lichen planus remains a subject of controversial 
discussions in the literature. hMSH2 is one of the human DNA mismatch 
repair (hMMR) genes and it plays an important role in reducing mutation 
and maintaining genomic stability. hMSH2 alterations have been reported in 
oral squamous cell carcinoma and there are evidences suggesting the 
association between oral lichen planus and squamous cell carcinoma. In this 
study, we aim to investigate the immunolocalization of hMSH2 protein in 
oral lichen planus compared to oral normal mucosa epithelium. We 
examined the expression of hMSH2 protein by immunohistochemistry in 
twenty-six cases of oral lichen planus. Clinically, 12 of them were categorized 
into reticular subtype and 14 were atrophic/erosive. Ten cases of normal 
mucosa were added to the control group. Results showed that the percentage 
of positive cells to hMSH2 was smaller in reticular (46.54%; p=0,006) and 
atrophic/erosive (48.79%; p=0,028) subtypes of oral lichen planus compared 
to normal mucosa (61.29%). The reduced expression of hMSH2 protein in 
oral lichen planus suggests that this lesion is more susceptible to mutation 
and therefore facilitate the development of oral  squamous cell carcinoma.  
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1.  Introduction 
Lichen planus is a chronic inflammatory mucocutaneous disease of unknown etiology that 
frequently involves the oral mucosa. The disease affects skin and mucosa in prevalence estimated 
between 0.5 and 2.0% of the population with predilection for females and a mean age at onset in the 
fourth or fifth decade [1]. Lichen planus affects the oral mucosa and lesions may occur without skin 
lesions. About half of the patients with skin lesions have oral lesions, whereas about 25% present with 
oral lesions alone [2]. 
Oral lichen planus (OLP) may present anywhere in the oral cavity. The buccal mucosa, tongue and 
gingival are the most common sites, whereas palatal lesions are uncommon [3]. They are usually 
symmetrical and bilateral lesions or multiple lesions may occur in the mouth [4]. OLP can appear 
clinically in at least six forms that can occur separately or simultaneously: reticular, papular, plaque, 
atrophic, erosive and bullous [2]. The reticular, papular, plaque-like forms are usually painless and 
appear clinically as white keratotic lesions. The erosive, atrophic and bullous forms are often associated 
with a burning sensation and in many cases can cause severe pain [5].  
The possible malignant transformation of OLP is a subject of controversial discussion in the 
literature. While some studies support a premalignant nature of OLP [6,7], others argue against the 
validity of this statement [8,9]. It has been reported that the actual overall frequency of OLP malignant 
transformation varies between 0.3 and 12.5% [6,9]. Analysis of the published data is difficult because 
of differences in diagnostic criteria, time to follow-up and information on exposure to known oral 
carcinogens [10]. The diagnostic criteria are major problem as there is no accepted standard [9]. 
Whether cancer development is part of the natural evolution of OLP lesions or is due to extrinsic factors 
is unknown [11]. However, the association between chronic inflammation with a variety of epithelial 
malignancies has been recognized [12]. There is now enough evidence to suggest that the inflammatory 
cells and cytokines found in peri-tumoural stroma can contribute to tumor development and progression 
rather than mount an effective host antitumor response [12].   
The human DNA mismatch repair (hMMR) system plays an important role in reducing mutation 
and maintaining genomic stability. It corrects base-base mismatches and short insertions/deletions 
generated as a consequence of DNA replication errors and homologous recombination [13]. MMR 
genes, including hMSH2, hMLH1, hMSH3, hMPS1, hPMS2 and GTBP/hMSH6 are very important in 
distinguishing and repairing misparing and slippage errors in DNA synthesis. The mismatch is detected 
by two complexes, the hMSH2-GTBP/hMSH6 and the hMSH2-hMSH3 heterodimers after interaction 
with hMLH1-hPMS2 heterodimers, an endonuclease is activated and incises the newly synthesized 
DNA strand that contains the mutation [14]. Immunohistochemical study on non-polyposis colorectal 
cancer demonstrated no expression of hMSH2 gene in the tumoral cells [15]. With regard to sporadic 
forms of tumors, reduced expression of hMSH2 have been reported in a distinct subset of oral and neck 
squamous cell [16], colorectal [17], endometrial [18], ovarian [19] and urinary bladder carcinomas [20]. 
As hMSH2 alterations have been reported in oral squamous cell carcinoma and there are evidences 
suggesting the association between oral lichen planus and squamous cell carcinoma, in this study, we 
aim to investigate the immunolocalization of hMSH2 protein in oral lichen planus compared to oral 
normal mucosa epithelium.  
2.  Materials and Methods 
Tissue Samples 
The material and methods have been approved by the ethical committee of Universidade Federal 
de Minas Gerais. Twenty-six samples of OLP diagnosed on clinical and histological criteria [21] were 
retrieved from the files of the Oral Pathology Service, Universidade Federal de Minas Gerais. Twelve 
OLP (six females and six males; age range from 27 to 61 years) were reticular clinical subtypes and 14 
were atrophic/erosive OLP (eight females and six males; age range from 19 to 65 years). Ten samples 
of oral normal mucosa were included in the control group (six males and four females; age range from 8 
to 67 years).  
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The hMSH2 protein staining was performed by the LSAB kit (DAKO, Carpinteria, USA). Briefly, 
3  µm sections were dewaxed in xylene and hydrated with graded ethanol.  Removal of formolic 
pigment was performed. Endogenous peroxidase was blocked by incubating sections in 6% (v/v) 
H2O2/methanol. Slides were placed in 10mM citrate buffer (pH 6.0) and heated to 96°C in a steamer for 
30 minutes and incubated with the primary antibody for 18 h at room temperature. The primary serum 
used were anti-hMSH2 (Clone G219-1129, Pharmingen, San Diego, USA) diluted 1:100 in 20 mmol/L 
Tris-HCl buffer (ph 7.4) containing 0.9% NaCl.   After washing in the Tris-HCl buffer, sections were 
incubated for 30 min at room temperature with biotinylated multi-link swine anti-goat, mouse and 
rabbit immunoglobulin. Sections were washed and incubated for 30 min at room temperature with 
prediluted streptavidin-peroxidase conjugated. The peroxidase activity was visualized by applying 
0.01% diaminobenzidine tetrahydrochloride and 0.03% H2O2. Sections were counterstained with 
Meyer’s haematoxylin and mounted in Permount
TM. Negative controls consisted of omission of the 
primary or the secondary antibody or primary incubation in the presence of non-immunized rabbit 
serum instead of the primary antibody.  
Cell quantification and Statistical analysis 
The immunolocalization of hMSH2 was quantitatively analyzed. Epithelial cells were considered 
to be positive if there was any staining of the nucleus, regardless of staining intensity. Cell counting was 
performed in six high-power microscopic fields (400x, Standard 20, ZEISS), which comprised almost 
all of the OLP epithelium. The count was performed by two investigators without knowledge of 
whether the samples were control or experimental. The total number of basal and suprabasal epithelial 
cells along the six microscopic fields and the number of basal and suprabasal cells stained to hMSH2 
protein were assessed. The percentage of cells stained to hMSH2 was obtained to each sample. As 
percentage does not conform normal distribution, the Mann-Whitney Test was used for statistical 
analysis. The values were considered significantly different when the p value was less than 0.05. 
3.  Results 
The hMSH2 immunoreativity was detected mainly in basal and intermediate epithelial layers (Fig. 
1 and 2). The mean percentage of positive epithelial cells to hMSH2 in OLP and oral normal mucosa 
were listed in table 1. The percentage of positive cells in reticular and atrophic/erosive subtypes of OLP 
was significantly decreased compared to oral normal mucosa (Table 1). No difference was detected 
between the reticular and atrophic/erosive subtypes. 
4.  Discussion 
Several conditions in oral pathology have been characterized as premalignant and many factors 
have been considered to promote the development of carcinoma in the oral cavity. An important 
question still relates to the precancerous potential of oral lichen planus [22]. Most studies have shown 
that patients with OLP develop oral cancer at an increased rate as compared with the general population 
[4,7,11]. Many articles are found in the literature suggesting an association of lichen planus to oral 
squamous cell carcinoma, but several of them suffer from poor documentation. The most common 
errors resulting in misleading conclusions are: the initial diagnostic errors, the inclusion of cases that 
had a known history of exposure to recognized carcinogens, and the report of cases of lichenoid 
dysplasia as malignant transformation of lichen planus. Despite differences in experimental designs, the 
majority of studies have reported a rate of malignant transformation of OLP between 0.5 and 2% over 
five-year period [23].   
OLP is a T-cell-mediated chronic inflammatory disorder of unknown etiology. Histopathologically 
it is characterized by a sub-epithelial lymphocytic infiltrate, disruption of epithelial basement 
membrane, degeneration of basal keratinocytes, hyperkeratinization and acanthosis [24]. Basal cells are 
the prime target of destruction in OLP. The mechanism of basal cell damage is related to a cell-
mediated immune process involving Langerhans cells, T lymphocytes and macrophages [5]. The 
majority of OLP-related T-cells are activated cytotoxic CD8
+ T-cells, which are known to trigger 
keratinocyte apoptosis via TNF-alpha release [25].  
The association between chronic inflammation with a variety of epithelial malignancies has been 
recognized. Examples of well known association between inflammation and cancer risk include, 
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cancer related to chronic cholecyistitis, and esophageal carcinoma after reflux esophagitis [12]. There is 
now enough evidence to suggest that in some instances inflammatory cells and cytokines found in 
peritumoral stroma can more likely contribute to tumor development and progression than to mount an 
effective host antitumoral response [12]. Recent studies have focused on the stromal inflammatory 
environment before the malignant lesions appear, and have underlined its active role during the 
transition from normal tissue to in situ and invasive carcinoma [26]. Stromal cells and their products, in 
association with insoluble intracellular matrix components, can act as an oncogenic agent, causing the 
disruption of homeostatic regulation of adjacent cells, such as tissue architecture, cell death and 
proliferation, and leading to the development of solid neoplasia, such as breast, colon and prostate 
carcinoma [27].  Additional studies are necessary to establish whether OLP could be classified among 
these chronic disorders. Many inflammatory factors known to be related with cancer initiation, 
progression, and invasion are also expressed by OLP-related chronic inflammatory infiltrate, and thus 
may contribute to OLP malignant transformation [24].  
hMSH2 is especially expressed in human cells that are undergoing rapid renewal: in the lower-two 
thirds of gastrointestinal glands [15], in the more primitive testicular germ cells [28], in the transitional 
epithelial cells of the bladder [20], and in the basal cell line of epidermis and oral mucosa [29]. 
Inactivation of hMSH2, one of the most commonly hMMR genes, is a described alternative pathway in 
cancer development and progression. The resulting genetic instability is characterized by somatic 
mutations in repetitive sequences of tumor DNA and is termed microsatellite instability [13]. Although 
described in a variety of tumors [17-20], hMMR deficiency has been studied predominantly in 
colorectal carcinomas. A distinct proportion of sporadic (and almost all hereditary) non-polyposis 
colorectal cancers exhibit hMSH2 gene alterations. These tumors show high frequency of microsatellite 
instability and are immunohistochemically characterized by the lack of hMSH2 protein expression [15]. 
Moreover, Lo Muzio et al. [29] reported that 5% of the cases of oral squamous cell carcinoma show 
diminished expression of hMSH2 protein.    
In the present study, we demonstrated decreased expression of hMSH2 protein in reticular and 
atrophic/erosive OLP compared to oral normal mucosa. This reduction probable occurred by the 
destruction of basal layer provoked by immune response. da Silva Fonseca & do Carmo [30] showed 
that OLP kerationocytes present higher PCNA index and AgNOR numbers than epithelial cells from 
normal mucosa, which suggests increased cellular proliferation in OLP. As DNA damage is more prone 
to occur during the cell cycle, it can be assumed that a higher index of cellular proliferation in OLP 
would require an increased immunolocalization of hMSH2. Therefore, the reduced expression of 
hMSH2 protein could make the epithelium of OLP more susceptible to DNA mutation, making it prone 
to oral squamous cell carcinoma development. Further studies are necessary to confirm this hypothesis. 
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Tables and Figures 
Table 1 Percentage of positive cells to hMSH2 proteins in reticular and atrophic/erosive subtypes of 
oral lichen planus (OLP) compared to oral normal mucosa. 
 Mean  Median  Value  P 
Normal mucosa  61.29  64.62   
Reticular OLP  43.88  42.54  P=0.008* 
Atrophic/Erosive  OLP  48.79  49.40  P=0.028* 
* Statistically different when compared to oral normal mucosa. No statistical difference was observed between 
OLP subtypes.  
Figure 1. Positive labelling for hMSH2 protein in basal and intermediate epithelial layers of reticular 
subtype of oral lichen planus patient (streptavidin-biotin amplified system, x 400). 
 
Figure 2. Increased labelling of hMSH2 protein in basal and intermediate epithelial layers of normal 
oral mucosa (streptavidin-biotin amplified system, x 400). 
   